Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. In the last few years, antibody-targeted therapy has emerged as an effective and encouraging treatment for patients with acute myeloid leukemia. Mylotarg (gemtuzumab zogamicin) (Wyeth-Ayerst Laboratories, Philadelphia, PA, USA) consists of recombinant humanized anti-CD33 monoclonal antibody conjugated to an antitumor antibiotic (calicheamicin). Mylotarg-induced remissions have been observed in patients with refractory or relapsed acute myeloid leukemia.
In the last few years, antibody-targeted therapy has emerged as an effective and encouraging treatment for patients with acute myeloid leukemia. Mylotarg (gemtuzumab zogamicin) (Wyeth-Ayerst Laboratories, Philadelphia, PA, USA) consists of recombinant humanized anti-CD33 monoclonal antibody conjugated to an antitumor antibiotic (calicheamicin). Mylotarg-induced remissions have been observed in patients with refractory or relapsed acute myeloid leukemia. 1 Reversible increases in levels of serum bilirubin and aminotransferases are common complications. 2 We describe a patient in whom hepatic venoocclusive disease (HVOD) developed after infusion with Mylotarg.
Case report
A 67-year-old woman with acute myeloid leukemia (M5A, normal cytogenetics) received induction chemotherapy with standard doses of idarubicin and cytarabine, followed by consolidation treatment with these agents. Intensification chemotherapy with high-dose cytarabine was given for three cycles. The patient had a relapse after 15 months and was treated by reinduction with idarubicin and cytarabine before undergoing autologous hematopoietic stem cell transplantation (after conditioning with cyclophosphamide and total body irradiation). The patient underwent transplantation without complications but unfortunately had a second relapse 8 months later. Intravenous Mylotarg was given shortly after the second relapse (9 mg/m 2 for two doses 14 days apart). The patient experienced epigastric pain 6 days after the initial drug infusion. On examination, she had right upper quadrant tenderness and abdominal distention. Bilirubin and alkaline phosphatase levels were normal, and transaminases were elevated by less than two-fold. date. Eleven days after the second Mylotarg infusion, alkaline phosphatase had increased to 1010 U/l, aspartate aminotransferase to 94 U/l, and bilirubin to 1.5 mg/dl. Transjugular liver biopsy was eventually performed 1 month after drug infusion and demonstrated marked sinusoidal congestion and dilation, intimal edema in terminal hepatic venules, and perivenular fibrosis (Figure 4) . Pressure readings demonstrated elevated hepatic venous pressure with a wedged hepatic venous pressure of 32 mm Hg and portal hypertension. The biopsy findings were consistent with HVOD. Bilirubin and aspartate aminotransferase levels continued to rise, to 3.1 mg/dl and 470 U/l, respectively, 1 month after initial infusion. A transjugular intrahepatic portosystemic shunt was ultimately required for intractable ascites 53 days after the initial Mylotarg infusion, and bilirubin had reached a peak level of 15.8 mg/dl. 
Discussion
The clinical syndrome of HVOD consists of left upper quadrant pain, weight gain, ascites, and jaundice. 3, 4 Although hepatic irradiation and a number of antineoplastic drugs have been implicated as causes, HVOD is most commonly seen after bone marrow and hematopoietic stem cell transplantation (HSCT). HVOD occurs in approximately 20% and 10% of patients undergoing allogeneic or autologous HSCT, respectively. 5 It usually begins within 30 days after HSCT, but onset may be delayed for up to 65 days. 3 Other causes of hyperbilirubinemia and ascites, such as graft-versus-host disease, Budd-Chiari syndrome, drug toxicities, and post-transfusion hepatitis, must be excluded. The primary lesion of HVOD begins with subendothelial edema and endothelial cell damage in hepatic venules. Fibrin deposition extends from terminal hepatic venules into the sinusoids, with subsequent narrowing and obliteration. Progression to hepatocyte necrosis is a late finding. Ultrasonography and computed tomography imaging are not diagnostic, but they can help to identify hepatomegaly and ascites and also to exclude portal vein thrombosis. The gold standard of diagnosis remains transvenous liver biopsy and hepatic venous pressure measurement. A wedged hepatic venous pressure gradient of more than 10 mm Hg is associated with a histological diagnosis of HVOD. 3, 5 The prognosis of HVOD ranges from a fulminant, fatal course to complete recovery. One study 4 reported death in 32% of patients, 13% with a prolonged course; 55% of patients had complete resolution. Treatment varies and includes therapies aimed at fibrinolysis, such as tissue plasminogen activator, heparin, prostaglandins, and urokinase. [3] [4] [5] Once fibrosis and necrosis have occurred, treatment is limited and includes transjugular intrahepatic portosystemic shunt or liver transplantation.
Mylotarg is a drug-antibody conjugate that is currently under investigation for the treatment of acute myeloid leukemia. The goal of systemic therapy is to selectively target the cytotoxic antibiotic to the myeloid cell-surface antigen CD33, which is expressed on most myeloid blast cells and does not appear on normal hematopoietic stem cells. Efficacy of antibody-targeted therapy has been observed in refractory or relapsed patients in a recent phase I study (20% in remission after treatment), and remission was induced in over one-third of patients with first relapse in a subsequent phase II study. 6 Adverse reactions are chiefly hematological and include neutropenia, thrombocytopenia, and anemia, occasionally reaching grade IV severity. Gastrointestinal side-effects include nausea, vomiting, mucositis, and hepatotoxicity. Reversible increases in levels of serum bilirubin and aminotransferases are seen in more than 50% of cases, with hyperbilirubinemia reaching grade IV severity in 25%. 7 Thus far, HVOD has not been reported as a complication of Mylotarg infusion.
The mechanism of Mylotarg-associated HVOD is not known. Prior studies have indicated that hepatic stellate cells play an important role in the pathogenesis of HVOD. 8 Mylotarg-associated HVOD may involve drug binding to resident liver cells that may express CD33, with resultant injury to hepatic stellate cells. 8 In summary, we believe that this is the first reported case of HVOD developing after Mylotarg therapy for acute myeloid leukemia. Although the patient underwent prior Bone Marrow Transplantation HSCT, the clinical syndrome of HVOD developed 8 months after transplantation and only 1 week after Mylotarg administration. This experience suggests that Mylotarg infusion for acute myeloid leukemia may be complicated by the development of HVOD and that patients who have previously undergone HSCT may be at increased risk. Physicians should be aware of the potential risk of HVOD when using Mylotarg. Patients should be monitored closely for signs of irreversible elevated levels of liver enzymes and bilirubin and for ascites, which may be an early sign of HVOD. Further studies are needed to define the association between Mylotarg and HVOD, especially in patients with prior HSCT.
